Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Borkon

Vascular Surgery Winchester, VA Medical Doctor

NPI 1972650778 CMS profile 362006

1880 Amherst St Ste 300, Ste 300, Winchester, VA 22601

Open in the dashboard

General payments

$14,972

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Borkon of Winchester, VA is reported in the CMS Open Payments database as having received $14,972 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $979 20
2024 General $916 22
2023 General $3,825 29
2022 General $861 21
2021 General $1,016 20
2020 General $168 8
2019 General $7,206 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Borkon
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Matthew Borkon were reported at $979. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Matthew Borkon Vascular Surgery median Middle half National median
2019 $7,206 $796 $226–$2,363 $163
2020 $168 $348 $118–$1,110 $114
2021 $1,016 $471 $158–$1,421 $132
2022 $861 $725 $222–$2,183 $149
2023 $3,825 $836 $257–$2,440 $160
2024 $916 $909 $252–$2,619 $164
2025 $979 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $7,298 39 payments
  2. Medtronic, Inc. $6,039 75 payments
  3. Janssen Pharmaceuticals, Inc $231 5 payments
  4. Bolton Medical Inc $211 4 payments
  5. Bard Peripheral Vascular, Inc. $196 2 payments
  6. Boston Scientific Corporation $192 2 payments
  7. Silk Road Medical, Inc. $163 4 payments
  8. W. L. Gore & Associates, Inc. $116 1 payment
  9. Shape Memory Medical Inc. $73 2 payments
  10. CryoLife, Inc. $72 1 payment
  11. Other $381 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $9,039 12 payments
  2. Food and Beverage $5,934 142 payments
Products named General payments · program years 2019–2025
  1. IN.PACT Admiral $6,649 16 payments
  2. Valiant Captivia $3,916 32 payments
  3. Heli-FX EndoAnchor System $923 18 payments
  4. ENDURANT IIS $627 13 payments
  5. Endurant Aortic Stent Grafts $511 8 payments
  6. Endurant Aortic Stent Grafts $501 18 payments
  7. XARELTO $231 5 payments
  8. TREO ABDOMINAL STENT-GRAFT SYSTEM $176 2 payments
  9. ENROUTE Transcarotid Neuroprotection System $169 1 payment
  10. ENROUTE Transcarotid Stent $163 4 payments
  11. Other $1,676 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

303

Median for Vascular Surgery: 122

Drug cost

$17,745

Median for Vascular Surgery: $14,135

Branded share of claims

71.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $16,081
Clopidogrel Clopidogrel Bisulfate Brand 194 $1,202
Atorvastatin Calcium Generic 72 $403
Methylprednisolone Generic 13 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$171,590

Medicare's payments for the services billed

Medicare patients

874

Average age 75

Services billed

1,630

397 women, 477 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 50%
Diabetes 42%
Chronic kidney disease 39%
COPD 31%
Heart failure 30%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record